- VernacularTitle:原发性纤毛运动障碍基因治疗的现状和展望
- Author:
Wanqing LU
1
;
Yixuan LI
1
;
Miao HE
2
;
Xinlun TIAN
3
;
Yaping LIU
1
Author Information
- Publication Type:Review
- Keywords: primary ciliary dyskinesia; gene replacement therapy; gene editing therapy; RNA therapy
- From: JOURNAL OF RARE DISEASES 2025;4(3):377-383
- CountryChina
- Language:Chinese
-
Abstract:
Primary ciliary dyskinesia (PCD) is a genetically heterogeneous disease characterized by structural or functional abnormalities of motile cilia. It often presents clinically with recurrent respiratory infections, situs inversus, hydrocephalus, and infertility. Currently, there is no clinical treatment to directly restore ciliary motility in PCD patients.In recent years, researchers have explored gene therapy methods such as gene replacement, gene editing, and RNA replacement
in vitro and in mouse models, offering potential new strategies for PCD treatment. This paper comprehensively reviews the current status of PCD gene therapy research, evaluates the potential of different gene therapies, and provides an outlook on the future treatment directions for this disease.

